Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.

Dana Chase, MD, is an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology at UCLA Health.

Unmet Needs and Future Research Focus for Endometrial Cancer

Panelists discuss how significant unmet needs persist in the treatment of endometrial cancer despite recent advances. They identify challenges such as improving outcomes in mismatch repair–proficient/microsatellite-stable disease, managing treatment resistance, and expanding therapeutic access for diverse populations. The discussion also highlights disparities in diagnosis and care delivery that continue to impact prognosis and quality of life.

The conversation turns toward the need for more personalized approaches, including better integration of molecular profiling, novel combinations, and real-world data to guide clinical practice. Panelists stress the importance of collaboration between researchers, clinicians, and policymakers to close existing gaps and ensure equitable innovation.

In closing, they emphasize that the future of endometrial cancer care will rely on maintaining momentum in translational research and prioritizing patient-centered strategies. Continued commitment to addressing these unmet needs will be critical for advancing survival and quality of life across all patient groups.

Videos

Panelists discuss how emerging therapies and biomarker-driven research are shaping the next wave of innovation in endometrial cancer treatment.

Emerging Treatment Considerations for Endometrial Cancer

Panelists discuss how ongoing research continues to broaden therapeutic horizons in endometrial cancer. They highlight promising investigational agents, including next-generation immune checkpoint inhibitors, antibody-drug conjugates, and targeted therapies that may enhance precision and overcome resistance. The discussion underscores how novel trial designs and biomarker-driven studies are accelerating innovation in this disease space.

Experts explore how new combinations aim to deepen and extend responses beyond what is achievable with current immunotherapies. They also touch on the integration of genomic profiling to identify molecular vulnerabilities that may inform future treatment algorithms. The panel notes that collaborative research efforts across academic and industry settings are essential for advancing patient care.

The session concludes with a forward-looking perspective, emphasizing the importance of maintaining clinical trial participation and fostering access to cutting-edge options. The panel remains optimistic about the continued evolution of endometrial cancer therapy in the era of immuno-oncology.

Panelists discuss how evolving immunotherapy combinations and NCCN guidelines shape frontline treatment selection for advanced or recurrent endometrial cancer.

Frontline Treatment Considerations in Endometrial Cancer

Panelists discuss how the introduction of pembrolizumab plus chemotherapy has expanded the landscape of frontline immunotherapy options for advanced or recurrent endometrial cancer. They compare this regimen with other checkpoint inhibitor combinations, focusing on key considerations for selecting the most appropriate therapy. Factors such as tumor biomarkers, previous treatment exposure, and patient-specific tolerability play a vital role in guiding clinical decisions.

The discussion emphasizes the role of established treatment guidelines, including NCCN recommendations, which provide evidence-based frameworks to navigate complex therapeutic choices. Panelists highlight that while multiple immunotherapy-based options are now available, optimal use depends on understanding differences in mechanism, toxicity, and long-term benefit.

In conclusion, the panel reflects on how these evolving standards of care represent a new era in endometrial cancer treatment. They advocate for continued data integration, clinician education, and guideline alignment to ensure consistent and effective application of immunotherapy in the frontline setting.

Panelists discuss how careful management of adverse events and quality-of-life factors optimizes the safe use of dostarlimab plus chemotherapy in endometrial cancer.

Adverse Event and Quality-of-Life Considerations in Endometrial Cancer

Panelists discuss how managing adverse events and maintaining quality of life are critical when using dostarlimab plus chemotherapy in endometrial cancer. They provide an overview of the regimen’s safety profile, noting common toxicities such as fatigue, gastrointestinal effects, and immune-related events like endocrinopathies or hepatic inflammation. The conversation underscores the importance of proactive monitoring and early intervention to ensure patients can continue therapy safely.

The experts outline practical strategies for managing treatment-related adverse effects, including patient education, multidisciplinary support, and routine lab monitoring. They emphasize that toxicity management should be integrated into the care plan from the outset, as immune-mediated reactions may occur unpredictably or even after therapy completion.

Finally, the panel stresses that individualized assessment—considering patient age, comorbidities, and baseline performance status—is essential to optimizing outcomes. Balancing treatment efficacy with tolerability and quality-of-life goals remains a cornerstone of care, ensuring that advances in immunotherapy translate to meaningful patient benefit.

Panelists discuss how survival data from the RUBY study highlight the benefits of dostarlimab plus chemotherapy in pMMR/MSS and older patient populations with advanced endometrial cancer.

RUBY Study Survival Analysis Informs Frontline Treatment Selection

Panelists discuss how findings from a post hoc survival analysis of the phase 3 RUBY study provide new insights into treatment outcomes for patients with primary advanced or recurrent endometrial cancer, particularly those with mismatch repair–proficient/microsatellite-stable (pMMR/MSS) disease. They explain that survival trends were analyzed based on both initial and subsequent therapies, offering a more comprehensive view of long-term benefit.

The conversation explores how this subgroup analysis supports the use of dostarlimab plus chemotherapy in a broader population, revealing sustained survival benefit even in patients without mismatch repair deficiency. Panelists also address how these data can guide clinicians in managing older patients, emphasizing considerations such as tolerability, comorbidity, and maintaining quality of life alongside survival outcomes.

In closing, the panel reflects on how these findings inform frontline treatment decision-making and future trial designs. They suggest that understanding the nuanced survival benefits across molecular subtypes will continue to refine personalized immunotherapy strategies for this challenging disease.

Panelists discuss how patient and disease characteristics guide the selection of frontline immunotherapy regimens in recurrent or metastatic endometrial cancer.

Frontline Considerations for Immunotherapy in Endometrial Cancer

Panelists discuss how clinicians can evaluate multiple factors when determining immunotherapy use in the first-line recurrent or metastatic endometrial cancer setting. They examine how tumor molecular subtype, prior therapies, patient comorbidities, and tolerability concerns influence regimen selection. The conversation highlights the increasing importance of multidisciplinary decision-making as treatment landscapes evolve.

Experts emphasize the need to balance efficacy with safety, considering how immune-related toxicities may affect long-term quality of life. They describe practical considerations such as assessing PD-L1 status, microsatellite instability, and mismatch repair deficiency, as well as emerging biomarkers that may refine treatment choice. Additionally, they review data supporting combination therapy versus single-agent strategies depending on disease burden and patient fitness.

In the concluding discussion, panelists stress the significance of tailoring therapy to the individual, rather than applying a one-size-fits-all model. They advocate for patient education, shared decision-making, and awareness of clinical trial opportunities that may expand future options for personalized care.

Panelists discuss how molecular testing enables precise categorization of endometrial cancer into biologically distinct subtypes that guide prognosis, therapy selection, and future research direction.

Molecular Subtypes of Endometrial Cancer

Panelists discuss how molecular testing has revolutionized the way clinicians categorize endometrial cancer, leading to a deeper understanding of disease biology and treatment personalization. They explain how advances in genomic profiling allow tumors to be classified into distinct molecular subtypes—such as POLE-ultramutated, mismatch repair–deficient, p53-abnormal, and no specific molecular profile. This framework moves beyond traditional histopathologic assessment, providing a more precise way to predict prognosis and guide therapeutic decisions.

The conversation explores how identifying these molecular categories can inform the likelihood of recurrence, response to therapy, and eligibility for targeted or immunotherapy approaches. Panelists emphasize that molecular testing is now becoming standard practice, allowing oncologists to move toward individualized care pathways rather than one-size-fits-all treatment plans. They highlight how these classifications are influencing ongoing research, clinical trial design, and guideline recommendations across multiple cancer care settings.

Finally, the discussion focuses on practical implementation, including testing accessibility, turnaround time, and integration into community practice. The panel underscores the importance of multidisciplinary collaboration between pathologists, oncologists, and genetic specialists to ensure molecular results are interpreted accurately and translated effectively into patient management strategies.

Bradley Monk, MD

Articles